Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanced Tissue Sciences Pursuing Dermagraft Cardiac Indications

This article was originally published in The Gray Sheet

Executive Summary

Pursuit of cardiovascular indications for Advanced Tissue Sciences' Dermagraft fibroblast tissue repair technology is likely to hinge upon finding a joint venture partner for the product, according to the La Jolla, California-based company.

You may also be interested in...



Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations

Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.

Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations

Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.

FDA Halts Vascular Genetics VEGF-2 Gene Therapy Heart Disease Trial

FDA has placed a gene therapy trial to promote angiogenesis in coronary heart disease patients on clinical hold. The study was being conducted by Vascular Genetics Inc., under the leadership of Jeff Isner, MD, chief of cardiovascular medicine at St. Elizabeth's Medical Center in Boston.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT013042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel